Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 8, 2016, Pages 1705-1714

  Roh, Seon Ae ^a,b   Park, In Ja ^a,b   Yoon, Yong Sik ^a,b   Kwon, Yi Hong ^a   Chung, Jin Hwa ^a   Kim, Tae Won ^a,b   Cho, Dong Hyung ^c   Lim, Byung Ho ^d   Kim, Seon Kyu ^d   Kim, Seon Young ^d   Kim, Yong Sung ^d   Kim, Jin Cheon ^a,b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Kyung Hee University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

ANXA11; Bevacizumab; Metastatic colorectal cancer; PPP1R15A; Predictive marker

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANNEXIN; PHOSPHOPROTEIN PHOSPHATASE 1; PPP1R15A PROTEIN, HUMAN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXA11 GENE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CHEMOSENSITIVITY; CHROMOSOME 19; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RESPONSE; DRUG UPTAKE; EXOME; FEASIBILITY STUDY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; METASTATIC COLORECTAL CANCER; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; PPP1R15A GENE; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; COLORECTAL NEOPLASMS; GENETICS; METASTASIS; PATHOLOGY;

ANIMALS; ANNEXINS; BEVACIZUMAB; COLORECTAL NEOPLASMS; FEASIBILITY STUDIES; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PHOSPHATASE 1;

EID: 84968677318     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-016-2177-5     Document Type: Article

References (24)

1. Ashktorab H, Daremipouran M, Devaney J et al (2015) Identification of novel mutations by exome sequencing in African American colorectal cancer patients. Cancer 121:34–42. doi:10.1002/cncr.28922
2. Celik B, Yalcin AD, Bisgin A, Dimitrakopoulou-Strauss A, Kargi A, Strauss LG (2013) Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-d-glucose uptake in anti-VEGF treated colon cancers. Med Sci Monit 19:875–882. doi:10.12659/msm.889605
3. Cifola I, Pietrelli A, Consolandi C et al (2013) Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling. PLoS ONE 8:e63597. doi:10.1371/journal.pone.0063597
4. De Angelis PM, Svendsrud DH, Kravik KL, Stokke T (2006) Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 5:20. doi:10.1186/1476-4598-5-20
5. De Mattia E, Cecchin E, Toffoli G (2015) Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist Updat 20:39–70. doi:10.1016/j.drup.2015.05.003
6. Fang LT, Lee S, Choi H et al (2014) Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis. Int J Oncol 44:211–221. doi:10.3892/ijo.2013.2150
7. Hegde PS, Jubb AM, Chen D et al (2013) Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19:929–937. doi:10.1158/1078-0432.ccr-12-2535
8. Hollander MC, Sheikh MS, Yu K et al (2001) Activation of Gadd34 by diverse apoptotic signals and suppression of its growth inhibitory effects by apoptotic inhibitors. Int J Cancer 96:22–31
9. Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172–1183. doi:10.1016/s1470-2045(10)70232-1
10. Kim JC, Kim SY, Cho DH et al (2011) Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clin Cancer Res 17:1200–1209. doi:10.1158/1078-0432.ccr-10-1907
11. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL (2013a) TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14:R36. doi:10.1186/gb-2013-14-4-r36
12. Kim JC, Ha YJ, Roh SA et al (2013b) Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer. Br J Cancer 108:1862–1869. doi:10.1038/bjc.2013.163
13. Koboldt DC, Zhang Q, Larson DE et al (2012) VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22:568–576. doi:10.1101/gr.129684.111
14. Koutras AK, Antonacopoulou AG, Eleftheraki AG et al (2012) Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 12:468–475. doi:10.1038/tpj.2011.37
15. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219–1230. doi:10.1200/jco.2012.46.2762
16. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25:1754–1760. doi:10.1093/bioinformatics/btp324
17. Liu X, Jian X, Boerwinkle E (2013) dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat 34:E2393–E2402. doi:10.1002/humu.22376
18. Luo HY, Xu RH (2014) Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol 20:3858–3874. doi:10.3748/wjg.v20.i14.3858
19. McKenna A, Hanna M, Banks E et al (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297–1303. doi:10.1101/gr.107524.110
20. Mertens J, De Bruyne S, Van Damme N et al (2013) Standardized added metabolic activity (SAM) IN (1)(8)F-FDG PET assessment of treatment response in colorectal liver metastases. Eur J Nucl Med Mol Imaging 40:1214–1222. doi:10.1007/s00259-013-2421-z
21. Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11:685–696. doi:10.1038/nrg2841
22. Pavlidis ET, Pavlidis TE (2013) Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol 19:5051–5060. doi:10.3748/wjg.v19.i31.5051
23. Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575. doi:10.1086/519795
24. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. doi:10.1093/jnci/92.3.205